



Original Article

Anti-inflammatory and hepatoprotective effects of *Moringa oleifera* fruit in obesity-induced liver injury

Tiwuk Susantiningsih^{1✉}, Maria Selvester Thadeus¹, Mila Citrawati¹, Yuni Setyaningsih¹

¹ Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, South Jakarta, Jakarta, 12450, Indonesia

ARTICLE INFORMATION

Received: March 03, 2026

Revised: April 15, 2026

Accepted: April 16, 2026

KEYWORDS

Moringa oleifera Fruits; Anti-inflammatory; Hepatoprotective; Obesity-induced Liver Injury; C-Reactive Protein

CORRESPONDENCE

Phone: +6287884011953

E-mail: tiwuksusantiningsih@upnvj.ac.id

ABSTRACT

Background: Hepatic metabolic disorders are closely associated with obesity and are characterized by systemic inflammation and liver injury. *Moringa oleifera* fruit contains various bioactive compounds with potential anti-inflammatory and hepatoprotective properties. However, evidence regarding its effects on obesity-induced liver injury remains limited.

Objective: This study aimed to evaluate the anti-inflammatory and hepatoprotective effects of *Moringa oleifera* fruit extract in an obesity-induced rat model.

Methods: This experimental study used 30 male Sprague-Dawley rats divided into five groups: normal control (N), obese control (O), obese rats treated with *Moringa oleifera* fruit extract at 500 mg/kg body weight once daily (OEMO1), twice daily (OEMO2), and obese rats treated with vitamin C (OC). Systemic inflammation was assessed by measuring serum C-reactive protein (CRP) levels using ELISA, while hepatic changes were evaluated through biochemical markers and histopathological analysis. Data were analyzed using one-way ANOVA followed by post hoc testing.

Results: Obese rats exhibited significantly elevated serum CRP levels and marked hepatic alterations compared to normal controls ($p < 0.05$). Administration of *Moringa oleifera* fruit extract significantly reduced CRP levels and improved hepatic histoarchitecture in obese rats, with the greatest effect observed in the twice-daily treatment group (OEMO2) ($p < 0.05$). The effects were comparable to or greater than those observed with vitamin C.

Conclusions: *Moringa oleifera* fruit extract demonstrates significant anti-inflammatory and hepatoprotective effects in an obesity-induced rat model, suggesting its potential as a natural therapeutic agent for obesity-related liver injury.

INTRODUCTION

Overweight and obesity are defined by the World Health Organization (WHO) as abnormal or excessive fat accumulation, with obesity classified as a body mass index (BMI) ≥ 30 kg/m², resulting from an imbalance between energy intake and expenditure. Globally, obesity has reached epidemic proportions, affecting more than 650 million adults.^{1,2} In Indonesia, obesity prevalence has increased significantly, reaching 15.4% among adults, highlighting a growing public health concern. Obesity is a major risk factor for various non-communicable diseases, including type 2 diabetes mellitus, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD), a recently updated term emphasizing the role of metabolic dysfunction in liver pathology.^{3,4}

<https://doi.org/10.30595/medisains.v24i1.30081>

©(2026) by the Medisains Journal. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at [Attribution-NonCommercial 4.0 International](https://creativecommons.org/licenses/by-nc/4.0/).

At the pathophysiological level, chronic caloric excess leads to excessive adipose tissue expansion beyond its physiological capacity, resulting in adipocyte hypertrophy, cellular stress, and adipose tissue inflammation. This condition is characterized by chronic low-grade systemic inflammation, marked by increased circulating inflammatory biomarkers such as C-reactive protein (CRP).⁵⁻⁷ Adipose tissue dysfunction and systemic inflammation contribute to hepatic lipid accumulation, oxidative stress, and insulin resistance, ultimately leading to hepatocellular injury and progression of MASLD. Although CRP is widely used as a marker of systemic inflammation, its role in reflecting the severity of obesity-related liver injury remains under debate.⁸

Previous studies have explored the potential of natural antioxidants in reducing obesity-related inflammation and

metabolic disturbances. *Moringa oleifera* has been widely investigated for its antioxidant, anti-inflammatory, and hepatoprotective effects, particularly its leaves, which have been shown to improve lipid metabolism and reduce inflammatory markers.^{9,10} Emerging evidence suggests that *Moringa oleifera* fruit contains higher concentrations of bioactive compounds, such as polyphenols, flavonoids, and isothiocyanates, which may provide stronger biological activity. However, studies specifically evaluating the effects of *M. oleifera* fruit on obesity-induced liver injury and systemic inflammation remain limited.

Moreover, the potential superiority of *M. oleifera* fruit compared to its leaves, as well as its role in modulating key inflammatory pathways associated with hepatic injury, has not been well established. Therefore, a clear research gap exists regarding the hepatoprotective and anti-inflammatory effects of *M. oleifera* fruit in obesity-related liver injury. This study aims to evaluate the anti-inflammatory and hepatoprotective effects of *Moringa oleifera* fruit extract on systemic inflammation, as indicated by CRP levels, and on liver injury in an obesity-induced experimental model.

METHOD

Study Design

This study was a randomized controlled experimental laboratory study.¹¹

Study Site

The study was conducted from June to December 2025 at the Animal Experimentation Laboratory and the Stem Cell Laboratory, Faculty of Medicine, Universitas Pembangunan Nasional "Veteran" Jakarta, Indonesia.

In Vivo Procedure

Animal Preparation

Thirty male Sprague-Dawley rats, aged 2–3 months and weighing 150–200 g, were used in this study. The animals were acclimatized for 7 days under standard laboratory conditions, housed in cages, and provided with BR II pellets and distilled water ad libitum. Obesity was induced using a high-fat diet administered for a defined experimental period. Rats were randomly assigned using a simple randomization method into five groups ($n = 6$ per group): normal control (N), obese control (O), obese rats treated with *M. oleifera* fruit extract once daily (OEMO1), obese rats treated with *M. oleifera* fruit extract twice daily (OEMO2), and obese rats treated with vitamin C (OC).

Preparation and Administration of *M. oleifera* Fruit Extract

M. oleifera fruits were processed and extracted using an ethanolic extraction method. The extract was administered orally at a dose of 500 mg/kg body weight once and twice daily according to the treatment protocol.

Experimental procedure of Systemic Inflammation and Hepatic Changes

Systemic inflammation was assessed by measuring serum C-reactive protein (CRP) levels using an enzyme-linked immunosorbent assay (ELISA) with the Elabscience® Rat CRP Kit (Catalog No. E-EL-R0506). Hepatic changes were evaluated through biochemical markers and histopathological examination. Liver tissues were stained using Hematoxylin–Eosin (HE) and examined under light microscopy to assess inflammatory infiltration and cellular morphology.

Statistical Analysis

Data distribution was assessed using the Shapiro–Wilk test. Differences among groups were analyzed using one-way ANOVA, followed by Tukey's post hoc test. A p -value < 0.05 was considered statistically significant.

Ethical Consideration

This study received ethical approval from the Health Research Ethics Committee of the Faculty of Medicine, Universitas Muhammadiyah Prof. Dr. HAMKA (UHAMKA), Indonesia (No. KEPKK/FK/068/06/2025).

RESULTS

Effect of *M. oleifera* Fruit Extract on CRP Levels

Administration of *Moringa oleifera* fruit extract significantly affected serum CRP levels among experimental groups (Figure 1). Obese control rats (O) exhibited markedly elevated CRP levels compared to normal controls (N) ($p < 0.05$), indicating systemic inflammation associated with obesity. Treatment with *M. oleifera* extract resulted in a significant reduction in CRP levels, with the greatest reduction observed in the twice-daily treatment group (OEMO2). The CRP levels in the OEMO2 group (1.600 ± 0.067) were lower than those in the normal control group (1.925 ± 0.077), suggesting a strong anti-inflammatory effect. Statistical analysis demonstrated significant differences among groups ($p < 0.0001$), while no significant difference was observed between the OEMO1 and OEMO2 groups.

Histopathological Changes in Liver Tissue

Histopathological examination of liver tissue using Hematoxylin–Eosin (HE) staining revealed distinct morphological differences among groups (Figure 2). The obese control group (O) showed marked hepatic alterations, including inflammatory cell infiltration and disrupted cellular architecture, consistent with obesity-induced liver injury. In contrast, rats treated with *M. oleifera* extract demonstrated improved hepatic morphology. The OEMO2 group exhibited reduced inflammatory infiltration, decreased cellular damage, and more organized hepatic structure, approaching normal histological features. The group treated with vitamin C (OC) showed moderate improvement compared to the obese control group but was less pronounced than that observed in the *M. oleifera* treatment groups.




Figure 1. Effect of *M. oleifera* fruit extract on serum CRP levels in an obesity-induced rat model..




Figure 2. Hematoxylin–eosin (HE)–stained liver sections showing histopathological changes among experimental groups (N: normal control; O: obese control; OEMO1: once-daily extract; OEMO2: twice-daily extract; OC: vitamin C-treated group).

DISCUSSION

This study demonstrates that *M. oleifera* fruit extract exerts significant anti-inflammatory and hepatoprotective effects in an obesity-induced rat model, as evidenced by reduced serum CRP levels and improved hepatic histopathology. The most pronounced effect was observed in the twice-daily treatment group, indicating a dose-frequency-dependent response.

Obesity-induced adipose tissue expansion is associated with chronic low-grade systemic inflammation, characterized by increased secretion of proinflammatory cytokines such as TNF- α , IL-6, and IL-1 β .^{12,13} Among these mediators, IL-6 plays a central role in stimulating hepatic

acute-phase responses, including CRP synthesis. Elevated CRP levels observed in the obese control group in this study reflect this inflammatory state.

CRP is synthesized by hepatocytes under IL-6–mediated activation of the JAK/STAT3 signaling pathway. Persistent elevation of IL-6 in obesity enhances CRP production, while oxidative stress and lipid accumulation further amplify inflammatory signaling within the liver.^{14–17} These processes contribute to hepatocellular injury and progression of obesity-related liver disease.

The reduction of CRP levels following administration of *M. oleifera* fruit extract observed in this study suggests effective attenuation of systemic inflammation. This effect is likely mediated by the high content of bioactive compounds, including polyphenols, flavonoids, and isothiocyanates. These compounds exert antioxidant effects by scavenging reactive oxygen species and enhancing endogenous antioxidant defenses, thereby suppressing NF- κ B activation and reducing proinflammatory cytokine production upstream of CRP synthesis.^{18–22}

The observed effect of *M. oleifera* fruit extract, which appeared greater than that of vitamin C, may reflect the synergistic action of multiple bioactive constituents. Unlike vitamin C, which primarily acts as a single antioxidant molecule, *M. oleifera* fruit exhibits pleiotropic effects by targeting oxidative stress, inflammatory pathways, and metabolic dysfunction simultaneously. This multimodal action is particularly relevant in obesity-related inflammation, which involves complex interactions between adipose tissue, liver, and systemic metabolism.^{23,24}

Histopathological findings further support these results. Treatment with *M. oleifera* fruit extract reduced inflammatory cell infiltration, decreased steatosis and hepatocellular ballooning, and improved hepatic architecture. These changes indicate reduced hepatic injury and improved cellular integrity. Activation of AMP-activated protein kinase by polyphenolic compounds may contribute to improved lipid metabolism and reduced hepatic triglyceride accumulation, thereby mitigating lipotoxic stress and oxidative damage.^{25,26}

These findings are consistent with previous studies demonstrating the anti-inflammatory and hepatoprotective effects of *M. oleifera*, particularly its leaves. However, evidence regarding the fruit remains limited. The present study supports the hypothesis that *M. oleifera* fruit may provide comparable or even enhanced biological effects due to its bioactive composition.

Despite these promising findings, this study has several limitations. First, the use of an animal model may limit the direct generalizability of the results to humans. Second, the study primarily assessed CRP as a marker of systemic inflammation without evaluating other key inflammatory cytokines or molecular signaling pathways. Third, the relatively small sample size may affect the robustness of the findings. Overall, this study highlights the potential of *M.*

oleifera fruit as a natural therapeutic agent targeting both systemic inflammation and liver injury in obesity, warranting further investigation in clinical studies.

CONCLUSIONS AND RECOMMENDATION

M. oleifera fruit extract demonstrates significant anti-inflammatory and hepatoprotective effects in an obesity-induced model, as evidenced by reduced systemic inflammation and improved hepatic histopathological features. The most pronounced effect observed in the twice-daily administration group suggests a potential dose-frequency-dependent response.

These findings highlight the potential of *M. oleifera* fruit as a natural therapeutic agent targeting metabolic and inflammatory pathways in obesity-related liver injury. Future studies should focus on elucidating the underlying molecular mechanisms and validating these findings in clinical settings.

REFERENCES

- World Health Organization. WHO European Regional Obesity Report 2022. WHO; 2022.: <https://iris.who.int/handle/10665/353747>
- Hildebrand S, Pfeifer A. The obesity pandemic and its impact on non-communicable disease burden. *Pflügers Archiv-European Journal of Physiology*. 2025 May;477(5):657-68.: <http://dx.doi.org/10.1007/s00424-025-03066-8>
- Roy A. Advances in non-alcoholic fatty liver disease (NAFLD) research and management: A global perspective (2020–2025). *Journal of Emerging Pharmaceutical and Medical Research (JEPMR)*. 2025 Aug 30:1-34. <https://jepmr.nknpub.com/1/article/view/6>
- Sharma S, Tiwari N, Tanwar SS. The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis. *Naunyn-Schmiedeberg's Archives of Pharmacology*. 2025 Apr 9:1-39. <http://dx.doi.org/10.1007/s00210-025-04069-z>
- Chew NW, Mehta A, Goh R, Koh J, Chen Y, Chong B, Chan MY, Khan MS, Muthiah MD, Butler J, Sanyal AJ. The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges. *Nature Reviews Cardiology*. 2025 Oct 6:1-20. <https://www.nature.com/articles/s41569-025-01220-4>
- Crasan IM, Tanase M, Delia CE, Gradisteanu-Pircalabioru G, Cimpean A, Ionica E. Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review. *International Journal of Molecular Sciences*. 2025 Oct 27;26(21):10445. <http://dx.doi.org/10.3390/ijms262110445>
- Béres D, Felső R, Herczeg R, Gyenesei A, Bokor S, Molnár D. C-reactive protein and metabolic syndrome in obese and normal weight Hungarian children. *Annals of Nutrition and Metabolism*. 2025 Mar 28. <https://karger.com/anm/article/81/4/213/924570/C-Reactive-Protein-and-Metabolic-Syndrome-in-Obese>
- Wang H, Ye J, Chen Y, Sun Y, Gong X, Deng H, Dong Z, Xu L, Li X, Zhong B. High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease. *BMC gastroenterology*. 2025 Apr 8;25(1):231. <http://dx.doi.org/10.1186/s12876-025-03778-2>
- Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a new disease definition. *Hepatology*. 2021;73(5):2027–35. <http://dx.doi.org/10.1002/hep.31420>
- Tilig H, Moschen AR. Inflammatory mechanisms in obesity. *Nat Rev Immunol*. 2006;6(10):772–83. <https://www.nature.com/articles/nri1937>
- Thadeus MS, Susantiningih T, Muktamiroh H, Fauziah C, Citrawati M, Irmarahayu A, Wahyuningsih S, Hadiwiardjo YH, Yusmaini H, Bahar M, Zulfa F. Moringa oleifera fruit extract as a potential antioxidant against liver injury by 2-nitropropane induction in obese male mice model: Pre-clinical study. *F1000Research*. 2024 Feb 12;12:300.: <http://dx.doi.org/10.12688/f1000research.121695.2>
- Ma Y, Yan S, Dong Y, Ma Y, Lai X, Jin X, Huang L, Sun Q. Alleviating Mechanism of Microencapsulated Compound Probiotics Against Obesity via PPAR Metabolic Pathway. *Probiotics and Antimicrobial Proteins*. 2026 Jan 6:1-8. <http://dx.doi.org/10.1007/s12602-025-10907-6>
- Chiş A, Noubissi PA, Pop OL, Mureşan CI, Fokam Tagne MA, Kamgang R, Fodor A, Sitar-Tăut AV, Cozma A, Orăşan OH, Hegheş SC. Bioactive compounds in Moringa oleifera: mechanisms of action, focus on their anti-inflammatory properties. *Plants*. 2023 Dec 20;13(1):20. <http://dx.doi.org/10.3390/plants13010020>
- Manjunath SH, Nataraj P, Swamy VH, Sugur K, Dey SK, Ranganathan V, Daniel S, Leihang Z, Sharon V, Chandrashekarappa S, Sajeev N. Development of Moringa oleifera as functional food targeting NRF2 signaling: Antioxidant and anti-inflammatory activity in experimental model systems. *Food & Function*. 2023;14(10):4734-51. <http://dx.doi.org/10.1039/D3FO00572K>
- Solsona-Vilarrasa E, Vousden KH. Obesity, white adipose tissue and cancer. *The FEBS Journal*. 2025 May;292(9):2189-207. <http://dx.doi.org/10.1111/febs.17312>
- Higos R, Renzi G, Taillandier P, Merabtene F, Rouault C, Abatan JB, Lambert M, Dugail I, Clément K, Marcelin G, Maqdasy S. How Adipocytes Orchestrate Inflammation Within Adipose Tissue?. *Biomolecules*. 2025 Dec 30;16(1):59.: <http://dx.doi.org/10.3390/biom16010059>
- Choi YW, Choi JH, Lee YS, Jeong J, Kang E, Park SH, Lee YK, Park SS, Kang HY, Kim YH, Park TJ. SLIT2 as a Key Regulator and Therapeutic Target in Liver Injury. *Molecular Therapy*. 2026 Jan 10. <http://dx.doi.org/10.1016/j.ymthe.2026.01.010>
- Jang HJ, Kang Y, Park EJ, Park E, Kim W, Lee S, Lee SW. Ethyl acetate fraction of Curcuma longa leaves suppresses IL 6 induced STAT3 activation via ERK

- signaling in Hep3B cells. *Biomedical Reports*. 2026 Mar 1;24(3):1-9. <http://dx.doi.org/10.3892/br.2026.2108>
19. Anggraini NW, Sulistyowati S, Soetrisno S, Purwanto B, Dirgahayu P. Effects of *Moringa oleifera* leaves on CRP, MDA, and alevels in a mouse model of preeclampsia. *Open Veterinary Journal*. 2025 Apr 30;15(4):1784. <http://dx.doi.org/10.5455/OVJ.2025.v15.i4.30>
 20. Villegas-Vazquez EY, Gómez-Cansino R, Marcelino-Pérez G, Jiménez-López D, Quintas-Granados LI. Unveiling the miracle tree: therapeutic potential of *Moringa oleifera* in chronic disease management and beyond. *Biomedicines*. 2025 Mar 5;13(3):634. <http://dx.doi.org/10.3390/biomedicines13030634>
 21. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860–7.: <https://www.nature.com/articles/nature05485>
 22. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol*. 2011;11(2):98–107. <https://www.nature.com/articles/nri2925>
 23. Sanyal AJ. Pathogenesis of nonalcoholic fatty liver disease. *Ann Hepatol*. 2005;4(1):S4–10. <https://academic.oup.com/oncolo/article-abstract/15/S4/14/6398937>
 24. Lee J, Koo N, Min DB. Reactive oxygen species, aging, and antioxidative nutraceuticals. *Compr Rev Food Sci Food Saf*. 2004;3(1):21–33. <http://dx.doi.org/10.1111/j.1541-4337.2004.tb00058.x>
 25. Leone A, Spada A, Battezzati A, Schiraldi A, Aristil J, Bertoli S. Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of *Moringa oleifera*. *Int J Mol Sci*. 2015;16(6):12791–835. <http://dx.doi.org/10.3390/ijms160612791>
 26. Sreelatha S, Padma PR. Antioxidant activity and total phenolic content of *Moringa oleifera* leaves. *Food Chem Toxicol*. 2009;47(9):2196–201. <http://dx.doi.org/10.17113/ftb.57.01.19.5877>